Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letters to Editor
  • Published:

Antitumour Activity in vitro Dependent on Immune B Lymphocytes

Nature New Biology volume 244, pages 209–211 (1973)Cite this article

Abstract

THE aim of this report is to show that B lymphocytes can be active against tumour cells in vitro. Lymphocytes from Balb/c mice in which primary Moloney sarcoma virus (MSV) tumours have regressed are active in vitro against target cells bearing the Moloney leukaemia virus (MLV) determined cell surface antigen but not against control cells which are MLV antigen negative1,2. Fractionation of the lymphocytes in this system has shown the active effector cells to be both thymus processed lymphocytes (T cells)3 and non-T cells3,4. Both subpopulations are active before peak tumour size and soon after regression3. The T cell activity rapidly fades following regression3, whereas the non T-cell activity persists in regressors, and by 30 d after virus infection the non-T cell activity is high and the T cell activity is low or undetectable3,4.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Strouk, V., Grundner, G., Fenyö, E. M., Lamon, E., Skurzak, H., and Klein, G., J. Exp. Med., 136, 344 (1972).

    Article  CAS  Google Scholar 

  2. Lamon, E. W., Skurzak, H. M., and Klein, E., Intern. J. Cancer, 10, 581 (1972).

    Article  CAS  Google Scholar 

  3. Lamon, E. W., Wigzell, H., Klein, E., Andersson, B., and Skurzak, H., J. Exp. Med., 137, 1472 (1973).

    Article  CAS  Google Scholar 

  4. Lamon, E. W., Skurzak, H. M., Klein, E., and Wigzell, H., J. Exp. Med., 136, 1072 (1972).

    Article  CAS  Google Scholar 

  5. Raff, M. C., Transplant. Rev., 6, 52 (1971).

    CAS  PubMed  Google Scholar 

  6. Wigzell, H., Sundqvist, K. G., and Yoshida, T. O., Scand. J. Immunol., 1, 75 (1972).

    Article  CAS  Google Scholar 

  7. Yoshida, T. O., and Andersson, B., Scand. J. Immunol., 1, 401 (1972).

    Article  CAS  Google Scholar 

  8. Basten, A., Sprent, J., and Miller, J. F. A. P., Nature New Biology, J. 235, 178 (1972).

    Article  CAS  Google Scholar 

  9. Lundgren, G., Zukoski, C. F., and Möller, G., Clin. Exp. Immunol., 3, 817 (1968).

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Takasugi, M., and Klein, E., Transplantation, 9, 219 (1970).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Tumour Biology, Karolinska Institute, Stockholm, 60

    E. W. LAMON, H. WIGZELL, B. ANDERSSON & E. KLEIN

Authors
  1. E. W. LAMON
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. WIGZELL
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. ANDERSSON
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. KLEIN
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

LAMON, E., WIGZELL, H., ANDERSSON, B. et al. Antitumour Activity in vitro Dependent on Immune B Lymphocytes. Nature New Biology 244, 209–211 (1973). https://doi.org/10.1038/newbio244209a0

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1038/newbio244209a0

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing